CD 9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma.

BMC Clinical Pathology
Ariel A WilliamsJames D Brooks

Abstract

Clear cell renal cell carcinoma (ccRCC) and chromophobe renal cell carcinoma (chRCC) can usually be distinguished by histologic characteristics. Occasionally, diagnosis proves challenging and diagnostic difficulty will likely increase as needle biopsies of renal lesions become more common. To identify markers that aid in differentiating ccRCC from chRCC, we used gene expression profiles to identify candidate markers that correlate with histology. 39 antisera and antibodies, including 35 for transcripts identified from gene expression profiling, were evaluated. Promising markers were tested on a tissue microarray (TMA) containing 428 renal neoplasms. Strength of staining of each core on the TMA was formally scored and the distribution of staining across different types of renal neoplasms was analyzed. Based on results from initial immunohistochemical staining of multitissue titer arrays, 23 of the antisera and antibodies were selected for staining of the TMA. For 7 of these markers, strength of staining of each core on the TMA was formally scored. Vimentin (positive in ccRCC) and CD9 (positive in chRCC) best distinguished ccRCC from chRCC. The combination of vimentin negativity and CD9 positivity was found to distinguish chRCC f...Continue Reading

References

Jan 1, 1996·The American Journal of Physiology·D Sheikh-HamadA García-Pérez
Apr 22, 1997·International Journal of Cancer. Journal International Du Cancer·M HigashiyamaM Miyake
Aug 1, 1997·The American Journal of Surgical Pathology·S K TickooR J Zarbo
Feb 19, 2000·The American Journal of Surgical Pathology·A K AveryC L Corless
Feb 13, 2001·Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·J KusukawaE Mekada
Apr 20, 2001·Proceedings of the National Academy of Sciences of the United States of America·V G TusherG Chu
Feb 23, 2002·The American Journal of Surgical Pathology·Mahul B AminMani Menon
Jun 29, 2002·Annals of Diagnostic Pathology·Joseph D KhouryGregory T MacLennan
Jul 16, 2002·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Sang Ling WuJohn H Connelly
Feb 25, 2003·The American Journal of Pathology·John P T HigginsJames D Brooks
Jan 9, 2004·Proceedings of the National Academy of Sciences of the United States of America·Jacques LapointeJonathan R Pollack
Feb 11, 2004·Cancer·Alessandro VolpeMichael A S Jewett
Aug 31, 2004·Oncogene·Cheng-long HuangMasayuki Miyake
Dec 30, 2004·Proceedings of the National Academy of Sciences of the United States of America·Qi CaiMaurice Burg
Apr 29, 2005·The Journal of Molecular Diagnostics : JMD·Audrey N SchuetzAndrew N Young
Aug 23, 2005·Journal of Immunotherapy·Melissa P UptonMichael B Atkins
Sep 1, 2005·Clinical & Experimental Metastasis·Koshi MimoriMasaki Mori
Oct 27, 2005·Current Pharmaceutical Design·Georg SauerHelmut Deissler
Dec 2, 2005·PLoS Medicine·Hongjuan ZhaoJames D Brooks
Mar 4, 2006·Seminars in Diagnostic Pathology·Brian F Skinnider, Mahul B Amin
Jan 12, 2007·The New England Journal of Medicine·Robert J MotzerRobert A Figlin
Jan 12, 2007·The New England Journal of Medicine·Bernard EscudierUNKNOWN TARGET Study Group
Mar 30, 2007·The American Journal of Pathology·Akiko KunitaNaoya Fujita
Jun 15, 2007·Current Opinion in Nephrology and Hypertension·Michael J CaplanAmy Duffield
Nov 13, 2007·The Journal of Urology·Brian R LaneSteven C Campbell
Jan 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Toni K ChoueiriBernard Escudier

❮ Previous
Next ❯

Citations

Jan 15, 2014·Nucleic Acid Therapeutics·Tatyana N ZamayAnna S Zamay
Jun 4, 2011·Cellular and Molecular Life Sciences : CMLS·Arun Satelli, Shulin Li
Feb 9, 2016·Biochemical and Biophysical Research Communications·Jo M GarnerLisa K Jennings
Jul 12, 2011·European Urology·Maxine SunPierre I Karakiewicz
Jul 9, 2011·Molecular Carcinogenesis·Ashwani KhuranaViji Shridhar
Mar 29, 2014·Frontiers in Oncology·Cristina GrangeGiovanni Camussi
Sep 11, 2018·Cancer Biomarkers : Section a of Disease Markers·Jianmin LiuYan Wang
Sep 27, 2018·Cells·Frida DanielssonAnnica Karin Britt Gad
Jul 17, 2014·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Z-G ShiG Liu
Apr 17, 2021·Frontiers in Immunology·Samantha J PastonLindy G Durrant

❮ Previous
Next ❯

Datasets Mentioned

BETA
GSE3538

Methods Mentioned

BETA
biopsy
cDNA array

Software Mentioned

Deconvoluter
SAM
TMA

Related Concepts

Related Feeds

Adenocarcinoma, Clear Cell

Clear Cell Adenocarcinoma is a tumor that arises in the female genital tract and is characterized by cells that appear clear under the microscope. Discover the latest research here.

Alpha-Synuclein Aggregation (MDS)

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.

Adhesion Molecules in Health and Disease

Cell adhesion molecules are a subset of cell adhesion proteins located on the cell surface involved in binding with other cells or with the extracellular matrix in the process called cell adhesion. In essence, cell adhesion molecules help cells stick to each other and to their surroundings. Cell adhesion is a crucial component in maintaining tissue structure and function. Discover the latest research on adhesion molecule and their role in health and disease here.